Remix Therapeutics
Associate Director, Strategy & Business Development at Remix Therapeutics supports corporate partnering and investor communications for a private biotech company focused on RNA processing therapeutics. The role serves as a key interface between scientific, executive, and external stakeholders to shape strategic opportunities and support fundraising. The position requires a strong scientific background and 3–5 years of relevant life‑sciences strategy or business development experience and is based onsite in Watertown, MA.
Headquarters
Watertown, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address disease drivers. The company's proprietary REMaster™ platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease-driving mRNAs and proteins, including historically undruggable targets. Its lead program, REM-422, is a first-in-class orally available small molecule mRNA degrader targeting MYB, with programs spanning oncology and other indications of high unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Remix Therapeutics.
Remix Therapeutics names Mythili Koneru as chief medical officer By Investing.com
Jan 6, 2026
Director, Corporate Development & Strategy
Artiva Biotherapeutics
Associate Director, Corporate Development
5AM Ventures
Associate, Focus Investment Partners
Focus Partners Wealth
Private Equity Investor Product Strategy, Associate
Blackstone
Distribution Strategy Lead - Australia
carlyle
Private Equity Investor Product Strategy, Associate
Blackstone